Compare Cytokinetics Inc (CYTK) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs L3Harris Technologies Inc — how do they compare? Cytokinetics Inc trades at $62.89 (market cap $8.62B), while L3Harris Technologies Inc trades at $236.8 (market cap $44.12B). The key difference: L3Harris Technologies Inc is far larger — about 5.1× Cytokinetics Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and L3Harris Technologies Inc for 56 Days on average.
| CYTK | LHX | |
|---|---|---|
Market Cap | $8.62B | $44.12B |
Volume | 2,594,626 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $87.26 | $378.48 |
52-Week Low | $54.76 | $233.63 |
Typical Hold Time | 19 Days | 56 Days |
Enterprise Value | $8.72B | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
LHX trades at $237.15, up 1.51% on the day, with a bearish technical signal from moving averages but strong fundamental performance, including three consecutive quarterly EPS beats. The company secured major defense contracts totaling over $10.7 billion in September 2026, supporting future revenue growth. Profit margins have improved steadily, with net income margin reaching 7.34% in 2025, and cash flow from operations strengthened to $3.11 billion.
The outlook is positive given robust contract wins and earnings momentum, but risks include ongoing legal investigations and high debt levels. Analyst consensus is strongly bullish with a $340 price target, implying significant upside from current levels, though technical indicators suggest near-term resistance around $238-$240.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
